Skip to main content
. 2021 Oct 27;16:7269–7281. doi: 10.2147/IJN.S331578

Figure 3.

Figure 3

In vitro cellular uptake and antitumor efficacy of ALA-PTX NPs. (A) Uptake of ALA-PTX NPs by MCF-7, MCF-7/ADR and HepG2 cells. *p<0.05, **p<0.01, compared with PTX injection; $p<0.05, $$p<0.01, compared with the ALA-PTX solution. (B) Endocytosis inhibitors co-incubated with ALA-PTX NPs in MCF-7, MCF-7/ADR and HepG2 cell to explore the endocytosis pathways. **p<0.01, compared with the cellular uptake of the no inhibitor treatment group (control).